Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jens Lundgren

Showing results (31-40 of 219) with videos related to

Pageof 22
Sort By:
The Journal of Infectious Diseases|July 24, 2020
Persistent COVID-19 in an Immunocompromised Patient Temporarily Responsive to Two Courses of Remdesivir TherapyMarie Helleberg, Carsten Utoft Niemann, Kasper Sommerlund Moestrup, et al.
International Journal of Cancer|March 7, 2019
Development and validation of a cycle-specific risk score for febrile neutropenia during chemotherapy cycles 2-6 in patients with solid cancers: The <sup>CSR</sup> FENCE scoreTheis Aagaard, Joanne Reekie, Ashley Roen, et al.
HIV Medicine|February 26, 2015
Why START? Reflections that led to the conduct of this large long-term strategic HIV trial, Jens Lundgren, Abdel Babiker, et al.
Frontiers in Immunology|December 10, 2021
Inflammation and Platelet Activation After COVID-19 Vaccines - Possible Mechanisms Behind Vaccine-Induced Immune Thrombocytopenia and ThrombosisSisse R Ostrowski, Ole S Søgaard, Martin Tolstrup, et al.
AIDS (London, England)|January 29, 2014
Predicted levels of HIV drug resistance: potential impact of expanding diagnosis, retention, and eligibility criteria for antiretroviral therapy initiationValentina Cambiano, Silvia Bertagnolio, Michael R Jordan, et al.
Frontiers in Immunology|September 5, 2022
Improved induced innate immune response after cART initiation in people with HIVMalene Hove-Skovsgaard, Dina Leth Møller, Annemette Hald, et al.
Trials|May 4, 2019
Efficacy of seven and fourteen days of antibiotic treatment in uncomplicated Staphylococcus aureus bacteremia (SAB7): study protocol for a randomized controlled trialLouise Thorlacius-Ussing, Christian Østergaard Andersen, Niels Frimodt-Møller, et al.
Plos One|August 21, 2012
Cost-effectiveness of tenofovir instead of zidovudine for use in first-line antiretroviral therapy in settings without virological monitoringViktor von Wyl, Valentina Cambiano, Michael R Jordan, et al.
Clinical Trials (London, England)|August 24, 2010
Regulatory impediments jeopardizing the conduct of clinical trials in Europe funded by the National Institutes of HealthJames D Neaton, Abdel Babiker, Mark Bohnhorst, et al.
AIDS (London, England)|December 4, 2004
Causes of death in HIV infection: the key determinant to define the clinical response to anti-HIV therapyAmanda Mocroft, Jose Gatell, Peter Reiss, et al.
Pageof 22

Showing results (31-40 of 219) with videos related to

Sort By:
Pageof 22
The Journal of Infectious Diseases|July 24, 2020
Persistent COVID-19 in an Immunocompromised Patient Temporarily Responsive to Two Courses of Remdesivir TherapyMarie Helleberg, Carsten Utoft Niemann, Kasper Sommerlund Moestrup, et al.
International Journal of Cancer|March 7, 2019
Development and validation of a cycle-specific risk score for febrile neutropenia during chemotherapy cycles 2-6 in patients with solid cancers: The <sup>CSR</sup> FENCE scoreTheis Aagaard, Joanne Reekie, Ashley Roen, et al.
HIV Medicine|February 26, 2015
Why START? Reflections that led to the conduct of this large long-term strategic HIV trial, Jens Lundgren, Abdel Babiker, et al.
Frontiers in Immunology|December 10, 2021
Inflammation and Platelet Activation After COVID-19 Vaccines - Possible Mechanisms Behind Vaccine-Induced Immune Thrombocytopenia and ThrombosisSisse R Ostrowski, Ole S Søgaard, Martin Tolstrup, et al.
AIDS (London, England)|January 29, 2014
Predicted levels of HIV drug resistance: potential impact of expanding diagnosis, retention, and eligibility criteria for antiretroviral therapy initiationValentina Cambiano, Silvia Bertagnolio, Michael R Jordan, et al.
Frontiers in Immunology|September 5, 2022
Improved induced innate immune response after cART initiation in people with HIVMalene Hove-Skovsgaard, Dina Leth Møller, Annemette Hald, et al.
Trials|May 4, 2019
Efficacy of seven and fourteen days of antibiotic treatment in uncomplicated Staphylococcus aureus bacteremia (SAB7): study protocol for a randomized controlled trialLouise Thorlacius-Ussing, Christian Østergaard Andersen, Niels Frimodt-Møller, et al.
Plos One|August 21, 2012
Cost-effectiveness of tenofovir instead of zidovudine for use in first-line antiretroviral therapy in settings without virological monitoringViktor von Wyl, Valentina Cambiano, Michael R Jordan, et al.
Clinical Trials (London, England)|August 24, 2010
Regulatory impediments jeopardizing the conduct of clinical trials in Europe funded by the National Institutes of HealthJames D Neaton, Abdel Babiker, Mark Bohnhorst, et al.
AIDS (London, England)|December 4, 2004
Causes of death in HIV infection: the key determinant to define the clinical response to anti-HIV therapyAmanda Mocroft, Jose Gatell, Peter Reiss, et al.
Pageof 22